Diabetes Trials Tend To Eschew Patient-Reported Outcomes
Executive Summary
A Pink Sheet analysis finds that most Phase III diabetes studies are not using patient-reported outcomes, which still tend to lack standardized measurements.
You may also be interested in...
Quality-Of-Life, Emotional Well-Being Becoming Highly Utilized PROs In Diabetes Trials
Industry mostly using the patient-reported outcomes as exploratory endpoints.
Diabetes Outcomes Trial Requirement Looks 'Increasingly Wise' – FDA’s Temple
FDA’s review of novel efficacy endpoints for diabetes therapies inevitably included discussion of the future of the cardiovascular outcomes study requirement for type 2 diabetes therapies; comments by FDA and EMA officials sure make it sound like the requirement isn’t going away any time soon.
Diabetes Trials Could Include Hypoglycemia As Patient-Reported Outcome
FDA, industry and patient advocates all want studies to move beyond HbA1c, but still need to develop common thresholds and definitions to support patient-reported outcomes in diabetes drug development.